- Erythropoietin (EPO) drugs, which stimulate red blood cell production, are essential in the treatment of anemia related to chronic kidney disease (CKD), chemotherapy, and other critical conditions, gaining increasing relevance in modern clinical protocols due to their therapeutic efficacy and expanding indications across various healthcare settings
- The rising demand for EPO drugs is primarily fueled by the growing global burden of CKD and cancer, the increasing aging population, and a heightened focus on improving patient outcomes in chronic care management
- North America dominated the erythropoietin (EPO) drugs market with the largest revenue share of 39% in 2024, supported by advanced healthcare infrastructure, high awareness levels, and a robust reimbursement framework, with the United States showing significant uptake of both branded and biosimilar EPO products driven by strategic collaborations and government-supported anemia management initiatives
- Asia-Pacific is expected to be the fastest growing region in the erythropoietin (EPO) drugs market during the forecast period due to improving access to healthcare services, rising prevalence of anemia-inducing conditions, and increased investment in biosimilar production by regional pharmaceutical firms
- Epoetin alfa segment dominated the erythropoietin (EPO) drugs market with a market share of 47% in 2024, driven by its long-standing clinical use, proven safety profile, and widespread availability across both developed and emerging markets
